Multivariate Pharma Technology Transfer Analysis: Civilization Diseases and COVID-19 Perspective
Abstract
:1. Introduction
2. Civilization Diseases and Technology Transfer Landscape
2.1. Technology Transfer Landscape
3. Methodology
- RQ1: What is the place of COVID-19 in relation to other civilization diseases in the technology transfer process?
- RQ2: Which civilization diseases have the highest importance in terms of technology transfer?
- Creating a matrix of objects and features
- 2.
- The second step of the calculation was to bring the different variables to comparable levels with standardization. As a result of diagnostic standardization, each variable will have a mean value of 0 and a standard deviation equal to 1. Standardization was made according to the following formula:
- 3.
- The third step was to estimate the z0—Positive Development Pattern (PDP)–by setting the maximum value for stimuli and the minimum value for destimuli in each column of standardized features. Again, all variables adopted were assumed to be stimuli.
- 4.
- The next step was calculating the distance of each object from the PDP, taking into account the impact of various strength characteristics on the studied phenomenon. The formula used to determine this distance is the Euclidean distance:
- The measure values are contained in the interval [0, 1], with the development measure calculated for a development pattern equal to one and for an anti-pattern equal to zero.
- The higher the level of the phenomenon, the higher the value of the measure.
- Quadrant 1—relatively high values of technology transfer transactions (SMTT_value) and relatively high number of transactions (SMTT_quantity).
- Quadrant 2—relatively low values of technology transfer transactions (SMTT_value) and relatively high number of transactions (SMTT_quantity).
- Quadrant 3—relatively low values of technology transfer transactions (SMTT_value) and relatively low number of transactions (SMTT_quantity).
- Quadrant 4—relatively high values of technology transfer transactions (SMTT_value) and relatively low number of transactions (SMTT_quantity).
4. Results
5. Discussion
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Appendix A
Grant | Partnership | Assets Transaction | Acquisition | Licensing | Private Equity | Venture Financing | Debt Offering | Equity Offering | Sum | |
---|---|---|---|---|---|---|---|---|---|---|
Lung cancer | 2542 | 24,186 | 3189 | 381,843 | 17,874 | 173 | 1153 | 0 | 3470 | 434,430 |
Brest cancer | 5055 | 6793 | 17,103 | 384,653 | 11,109 | 108 | 956 | 314 | 3313 | 429,404 |
Cardiovascular | 13,629 | 15,606 | 6418 | 298,670 | 21,126 | 2721 | 2249 | 4167 | 6584 | 371,170 |
Diabetes | 22,001 | 7866 | 13,479 | 230,295 | 20,297 | 563 | 2873 | 4035 | 4257 | 305,666 |
Obesity | 8961 | 1063 | 334 | 260,320 | 7901 | 648 | 594 | 1722 | 1334 | 282,877 |
Bladder cancer | 283 | 9132 | 28 | 160,015 | 3029 | 80 | 186 | 19 | 1753 | 174,525 |
Neurodegenerative | 3277 | 8327 | 189 | 104,680 | 11,197 | 129 | 2519 | 3030 | 2556 | 135,904 |
Pancreatic cancer | 1232 | 2774 | 4423 | 89,562 | 3281 | 68 | 182 | 15 | 1370 | 102,907 |
AIDS | 13,922 | 6741 | 1292 | 50,903 | 4178 | 126 | 75 | 2610 | 553 | 80,400 |
Prostate cancer | 2488 | 9030 | 3016 | 34,245 | 5741 | 100 | 863 | 1 | 2160 | 57,644 |
Allergies | 1618 | 4639 | 26,998 | 9518 | 4397 | 678 | 509 | 33 | 2671 | 51,061 |
COVID-19 | 1823 | 5116 | 280 | 6695 | 4608 | 1730 | 1964 | 3047 | 5824 | 31,086 |
Depression | 5898 | 548 | 2780 | 897 | 6556 | 108 | 2852 | 500 | 494 | 20,633 |
Chronic obstructive pulmonary disease | 763 | 4232 | 2110 | 1582 | 2386 | 200 | 206 | 1 | 109 | 11,589 |
Sum | 83,492 | 106,053 | 81,639 | 2,013,878 | 123,680 | 7432 | 17,181 | 19,494 | 36,448 |
Grant | Partnership | Assets Transaction | Acquisition | Licensing | Private Equity | Venture Financing | Debt Offering | Equity Offering | Sum | |
---|---|---|---|---|---|---|---|---|---|---|
Diabetes | 56,967 | 340 | 33 | 66 | 186 | 13 | 168 | 15 | 110 | 57,898 |
Cardiovascular | 29,749 | 229 | 53 | 82 | 141 | 18 | 123 | 18 | 93 | 30,506 |
AIDS | 27,796 | 139 | 23 | 27 | 57 | 6 | 17 | 2 | 21 | 28,088 |
Obesity | 22,559 | 78 | 16 | 22 | 69 | 7 | 49 | 5 | 42 | 22,847 |
Depression | 15,616 | 52 | 11 | 26 | 39 | 3 | 31 | 2 | 14 | 15,794 |
Brest cancer | 13,776 | 193 | 20 | 19 | 122 | 3 | 50 | 4 | 69 | 14,256 |
Neurodegenerative | 8854 | 144 | 10 | 21 | 70 | 6 | 90 | 12 | 79 | 9286 |
Prostate cancer | 6810 | 124 | 17 | 23 | 79 | 3 | 35 | 1 | 42 | 7134 |
Lung cancer | 6524 | 237 | 12 | 13 | 130 | 5 | 43 | 0 | 57 | 7021 |
Pancreatic cancer | 3787 | 97 | 10 | 7 | 44 | 5 | 28 | 3 | 43 | 4024 |
Allergies | 2588 | 122 | 19 | 29 | 55 | 9 | 46 | 6 | 45 | 2919 |
COVID-19 | 2072 | 413 | 11 | 33 | 191 | 22 | 56 | 11 | 101 | 2910 |
Chronic obstructive pulmonary disease | 1759 | 53 | 10 | 5 | 31 | 3 | 10 | 1 | 11 | 1883 |
Bladder cancer | 824 | 50 | 1 | 2 | 28 | 1 | 16 | 1 | 30 | 953 |
Sum | 199,681 | 2271 | 246 | 375 | 1242 | 104 | 762 | 81 | 757 |
Grant | Partnership | Assets Transaction | Acquisition | Licensing | Private Equity | Venture Financing | Debt Offering | Equity Offering | |
---|---|---|---|---|---|---|---|---|---|
AIDS | 0.50 | 48.50 | 56.17 | 1885.30 | 73.30 | 21.00 | 4.41 | 1305.00 | 26.33 |
Allergies | 0.63 | 38.02 | 1420.95 | 328.21 | 79.95 | 75.33 | 11.07 | 5.50 | 59.36 |
Bladder cancer | 0.34 | 182.64 | 28.00 | 80,007.50 | 108.18 | 80.00 | 11.63 | 19.00 | 58.43 |
Brest cancer | 0.37 | 35.20 | 855.15 | 20,244.89 | 91.06 | 36.00 | 19.12 | 78.50 | 48.01 |
Cardiovascular | 0.46 | 68.15 | 121.09 | 3642.32 | 149.83 | 151.17 | 18.28 | 231.50 | 70.80 |
Chronic obstructive pulmonary disease | 0.43 | 79.85 | 211.00 | 316.40 | 76.97 | 66.67 | 20.60 | 1.00 | 9.91 |
COVID-19 | 0.88 | 12.39 | 25.45 | 202.88 | 24.13 | 78.64 | 35.07 | 277.00 | 57.66 |
Depression | 0.38 | 10.54 | 252.73 | 34.50 | 168.10 | 36.00 | 92.00 | 250.00 | 35.29 |
Diabetes | 0.39 | 23.14 | 408.45 | 3489.32 | 109.12 | 43.31 | 17.10 | 269.00 | 38.70 |
Lung cancer | 0.39 | 102.05 | 265.75 | 29,372.54 | 137.49 | 34.60 | 26.81 | X | 60.88 |
Neurodegenerative | 0.37 | 57.83 | 18.90 | 4984.76 | 159.96 | 21.50 | 27.99 | 252.50 | 32.35 |
Obesity | 0.40 | 13.63 | 20.88 | 11,832.73 | 114.51 | 92.57 | 12.12 | 344.40 | 31.76 |
Pancreatic cancer | 0.33 | 28.60 | 442.30 | 12,794.57 | 74.57 | 13.60 | 6.50 | 5.00 | 31.86 |
Prostate cancer | 0.37 | 72.82 | 177.41 | 1488.91 | 72.67 | 33.33 | 24.66 | 1.00 | 51.43 |
References
- World Health Organization. Constitution. Available online: https://www.who.int/about/governance/constitution (accessed on 22 June 2022).
- World Health Organization. About WHO. Available online: https://www.who.int/about (accessed on 22 June 2022).
- World Health Organization. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19. 11 March 2020. Available online: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (accessed on 22 June 2022).
- Universal Declaration of Human Rights. United Nations—Human Rights—Office of the High Commissioner. 1948. Available online: https://www.ohchr.org/en/universal-declaration-of-human-rights (accessed on 22 June 2022).
- United Nations—Department of Economic and Social Affairs [UN-DESA]. Sustainable Development. 2022. Available online: https://sdgs.un.org/goals (accessed on 22 June 2022).
- Encyclopedia Britannica. Available online: https://www.britannica.com/science/disease (accessed on 22 June 2022).
- Fegg, M.; Kraus, S.; Graw, M.; Bausewein, K. Physical compared to mental diseases as reasons for committing suicide: A retrospective study. BMC Palliat. Care 2016, 15, 14. [Google Scholar] [CrossRef] [Green Version]
- Kendell, R.E. The distinction between mental and physical illness. Br. J. Psychiatry 2001, 178, 490–493. [Google Scholar] [CrossRef] [Green Version]
- Grzywa, A.; Makara-Studzińska, M.; Grzywa-Celińska, A. Zaburzenia psychiczne a choroby somatyczne. Curr. Probl. Psychiatry 2011, 12, 67–72. Available online: https://ruj.uj.edu.pl/xmlui/bitstream/handle/item/244299/grzywa_makara-studzinska_grzywa-celinska_zaburzenia_psychiczne_a_choroby_somatyczne_2011.pdf (accessed on 25 June 2022).
- Dudek, D.; Sobański, J.A. Mental disorders in somatic diseases: Psychopathology and treatment. Polskie Arch. Med. Wewnętrznej 2012, 122, 624–629. [Google Scholar] [CrossRef] [Green Version]
- Sangkatip, W.; Phuboon-ob, J. Non-Communicable Diseases Classification using Multi-Label Learning Techniques. In Proceedings of the 5th International Conference on Information Technology (InCIT), Chonburi, Thailand, 21–22 October 2020. [Google Scholar] [CrossRef]
- Ostrzyżek, A. Jakość życia w chorobach przewlekłych. Probl. Hig. Epidemiol. 2008, 89, 467–470. Available online: http://www.phie.pl/pdf/phe-2008/phe-2008-4-467.pdf (accessed on 26 June 2022).
- Kitajewska, W.; Szeląg, W.; Kopański, Z.; Maslyak, Z.; Sklyarov, I. Choroby cywilizacyjne i ich prewencja. J. Clin. Healthc. 2014, 1, 3–7. Available online: http://www.jchc.eu/numery/2014_1/201411.pdf (accessed on 26 June 2022).
- Jaikumar, S.; Dutta, S.; Sood, N. Impact of lifestyle diseases on income and household consumption: Evidence from an emerging economy. Health Mark. Q. 2021, 38, 35–49. [Google Scholar] [CrossRef]
- Carrera-Bastos, P.; Fontes-Villalba, M.; O’Keefe, J.H.; Lindeberg, S.; Cordain, L. The western diet and lifestyle and diseases of civilization. Res. Rep. Clin. Cardiol. 2011, 2, 15–35. [Google Scholar] [CrossRef] [Green Version]
- Osińska, M.; Kazberuk, A.; Celińska-Janowicz, K.; Zadykowicz, R.; Rysiak, E. Depresja—Choroba cywilizacyjna XXI wieku. Geriatria 2017, 11, 123–129. Available online: https://www.akademiamedycyny.pl/home-3-3/geriatria/archiwum/20173-2/ (accessed on 26 June 2022).
- Wyszkowska, Z. Wybrane koszty społeczne chorób cywilizacyjnych na przykładzie astmy i cukrzycy. Folia Pomer. Univ. Technol. Stetin. 2016, 329, 157–164. [Google Scholar] [CrossRef]
- Dharssi, S.; Wong-Rieger, D.; Harold, M.; Terry, S. Review of 11 national policies for rare diseases in the context of key patient needs. Orphanet J. Rare Dis. 2017, 12, 63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kalinowska-Sługocka, A.; Sługocki, J. Problemy ochrony zdrowia osób cierpiących na rzadkie choroby na przykładzie regulacji dotyczących tzw. sierocych produktów leczniczych. Stud. Z Zakr. Nauk. Prawnoustrojowych. Misc. 2012, 2, 47–54. Available online: https://bazhum.muzhp.pl/media//files/Studia_z_zakresu_nauk_prawnoustrojowych_Miscellanea/Studia_z_zakresu_nauk_prawnoustrojowych_Miscellanea-r2012-t2/Studia_z_zakresu_nauk_prawnoustrojowych_Miscellanea-r2012-t2-s47-54/Studia_z_zakresu_nauk_prawnoustrojowych_Miscellanea-r2012-t2-s47-54.pdf (accessed on 20 June 2022).
- Nuijten, M. Pricing Zolgensma—The world’s most expensive drug. J. Mark. Access. Health Policy 2021, 10, 2022353. [Google Scholar] [CrossRef] [PubMed]
- WHO. WHO releases new International Classification of Diseases (ICD 11). Available online: https://www.who.int/news/item/18-06-2018-who-releases-new-international-classification-of-diseases-(icd-11) (accessed on 20 June 2022).
- World Health Organization. International Classification of Diseases 11th Revision. 2022. Available online: https://icd.who.int/en/ (accessed on 21 June 2022).
- Bourcier Béquaert, B.; Baïada Hirèche, L.; Sachet Milliat, A. Cure or Sell: How Do Pharmaceutical Industry Marketers Combine Their Dual Mission? An Approach Using Moral Dissonance. J. Bus. Ethics 2022, 175, 555–581. [Google Scholar] [CrossRef]
- Horwitz, I.L.; Jones, S.A.; Cerfolio, R.J.; Fritz, F.; Greco, J.; Rudy, B.; Petrilli, M.C. Trends in COVID-19 Risk-Adjusted Mortality Rates. J. Hos. Med. 2021, 16, 90–92. [Google Scholar] [CrossRef]
- Alessandretti, L. What human mobility data tell us about COVID-19 spread. Nat. Rev. Phys. 2022, 4, 12–13. [Google Scholar] [CrossRef]
- Yip, M. We have never been so bounded: Pandemic, territoriality, and mobility. Geogr. J. 2021, 187, 174–181. [Google Scholar] [CrossRef]
- Bucciarelli, V.; Nasi, M.; Bianco, F.; Seferovic, J.; Ivkovic, V.; Gallina, S.; Mattioli, A.V. Depression pandemic and cardiovascular risk in the COVID-19 era and long COVID syndrome: Gender makes a difference. Trends Cardiovasc. Med. 2022, 32, 12–17. [Google Scholar] [CrossRef]
- Burkitt, D.P. Some diseases characteristic of modern Western civilization. Br. Med. J. 1973, 1, 274. [Google Scholar] [CrossRef] [Green Version]
- Marani, M.; Katul, G.G.; Pan, W.K.; Parolali, A.J. Intensity and frequency of extreme novel epidemics. Proc. Natl. Acad. Sci. USA 2021, 118, 35. [Google Scholar] [CrossRef]
- Hart, E. Diet in Disease: XXII.-Under-Feeding and Over-Eating. Hosp. 1893, 14, 117–118. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5255641/pdf/hosplond70103-0005.pdf (accessed on 20 September 2022).
- Kuryłowicz, W.; Kopczyński, J. Diseases of civilization, today and tomorrow. Mircen. J. Appl. Microbiol. Biotechnol. 1986, 2, 253–265. [Google Scholar] [CrossRef]
- Robinson, T.N. The epidemic of pediatric obesity. West. J. Med. 2000, 173, 220–221. [Google Scholar] [CrossRef] [Green Version]
- Żukiewicz-Sobczak, W.; Wróblewska, P.; Zwoliński, J.; Chmielewska-Badora, J.; Adamczuk, P.; Krasowska, E.; Zagórski, J.; Oniszczuk, A.; Piątek, J.; Silny, W. Obesity and poverty paradox in developed countries. Ann. Agric. Environ. Med. 2014, 21, 590–594. [Google Scholar] [CrossRef] [Green Version]
- Melnik, B.C.; John, S.M.; Schmitz, G. Milk consumption during pregnancy increases birth weight, a risk factor for the development of diseases of civilization. J. Transl. Med. 2015, 13, 13. [Google Scholar] [CrossRef]
- Pacian, A.; Kulik, T.; Szwedo, E. Lyme Borreliosis as a Current Health Problem of the 21st Century. Health Probl. Civiliz. 2017, 11, 66–70. [Google Scholar] [CrossRef]
- Sygit, K. Health problems of seniors: Selected diseases of the old age. Health Probl. Civiliz. 2018, 12, 33–40. [Google Scholar] [CrossRef]
- Clatici, V.G.; Voicu, C.; Voaides, C.; Roseanu, A.; Icriverzi, M.; Jurcoane, S. Diseases of Civilization—Cancer, Diabetes, Obesity and Acne—The Implication of Milk, IGF-1 and mTORC1. Maedica 2018, 13, 273–281. [Google Scholar] [CrossRef]
- Chakraborty, I.; Maity, P. COVID-19 outbreak: Migration, effects on society, global environment and prevention. Sci. Total Environ. 2020, 728, 138882. [Google Scholar] [CrossRef]
- Mazur, A.; Zachurzok, A.; Baran, J.; Dereń, K.; Łuszczki, E.; Weres, A.; Wyszyńska, J.; Dylczyk, J.; Szczudlik, E.; Drożdż, D.; et al. Childhood Obesity: Position Statement of Polish Society of Pediatrics, Polish Society for Pediatric Obesity, Polish Society of Pediatric Endocrinology and Diabetes, the College of Family Physicians in Poland and Polish Association for Study on Obesity. Nutrients 2022, 14, 3806. [Google Scholar] [CrossRef]
- Selman, A.; Burns, S.; Reddy, A.P.; Culberson, J.; Reddy, P.H. The Role of Obesity and Diabetes in Dementia. Int. J. Mol. Sci. 2022, 23, 9267. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Xu, H.; Shan, S.; Lu, Y.; Duan, H. The Impact of Ecological Civilization Construction on Environment and Public Health-Evidence from the Implementation of Ecological Civilization Demonstration Area in China. Int. J. Environ. Res. Public Health 2022, 19, 5361. [Google Scholar] [CrossRef] [PubMed]
- Kocarnik, J.M. Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022, 8, 420–444. [Google Scholar] [CrossRef] [PubMed]
- Statista. 2022. Available online: www.statista.com (accessed on 9 October 2022).
- Etzkowitz, H.; Leydesdorff, L. The dynamics of innovation: From National Systems and “Mode 2” to a Triple Helix of university–industry–government relations. Res. Policy 2000, 29, 109–123. [Google Scholar] [CrossRef]
- Mazzucato, M. The Entrepreneurial State: Debunking Public vs. Private Sector Myths; Anthem Press: London, UK, 2013. [Google Scholar]
- Casaramona, A.; Sapia, A.; Soraci, A. How TOI and the Quadruple and Quintuple Helix Innovation System Can Support the Development of a New Model of International Cooperation. J. Knowl. Econ. 2015, 6, 505–521. [Google Scholar] [CrossRef]
- Carayannis, E.G.; Campbell, D.F.; Grigoroudis, E. Helix trilogy: The triple, quadruple, and quintuple innovation helices from a theory, policy, and practice set of perspectives. J. Knowl. Econ. 2022, 13, 2272–2301. [Google Scholar] [CrossRef]
- O’Kane, C.; Cunningham, J.A.; Menter, M.; Walton, S. The brokering role of technology transfer offices within entrepreneurial ecosystems: An investigation of macro–meso–micro factors. J. Technol. Transf. 2021, 46, 1814–1844. [Google Scholar] [CrossRef]
- Marques, C.; Marques, A.V.; Braga, V.; Ratten, V. Technological transfer and spillovers within the RIS3 entrepreneurial ecosystems: A quadruple helix approach. Knowl. Manag. Res. Pract. 2021, 19, 127–136. [Google Scholar] [CrossRef]
- Ockwell, D.; Byrne, R. Improving technology transfer through national systems of innovation: Climate relevant innovation-system builders (CRIBs). Clim. Policy 2016, 16, 836–854. [Google Scholar] [CrossRef] [Green Version]
- da Silva, V.L.; Kovaleski, J.L.; Pagani, R.N. Fundamental elements in Technology Transfer: An in-depth analysis. Technol. Anal. Strateg. Manag. 2022, 34, 223–244. [Google Scholar] [CrossRef]
- Bozeman, B. Technology transfer and public policy: A review of research and theory. Res. Pol. 2000, 29, 627–655. [Google Scholar] [CrossRef]
- Hamidi, A.; Boog, C.; Jadhav, S.; Kreeftenberg, H. Lessons learned during the development and transfer of technology related to a new Hib conjugate vaccine to emerging vaccine manufacturers. Vaccine 2014, 32, 4124–4130. [Google Scholar] [CrossRef]
- Gomes, M.; Kovaleski, J.L.; Pagani, R.N.; Zammar, G. Government Initiative in Brazilian Public Health: A Technology Transfer Analysis. Int. J. Environ. Res. Public Health 2019, 16, 3012. [Google Scholar] [CrossRef] [Green Version]
- Cariati, F.; D’Argenio, V.; Izquierdo, R.; Tomaiuolo, R. From laboratory bench to benchmark: Technology transfer in laboratory medicine. Ann. Transl. Med. 2020, 8, 353. [Google Scholar] [CrossRef]
- Duvall, J.; Grindle, G.G.; Kaplan, J.; Lain, M.; Cooper, R.A. Technology Transfer Assistance Project Brings VA Health Care Ideas to Life. Technol. Innov. 2021, 22, 65–73. [Google Scholar] [CrossRef]
- Medeiros, M.Z.; Soares, P.F.; Fialho, B.C.; Gauss, L.; Piran, F.S.; Lacerda, D.P. Vaccine innovation model: A technology transfer perspective in pandemic contexts. Vaccine 2022, 40, 4748–4763. [Google Scholar] [CrossRef]
- Liang, W.; Elrod, S.; McFarland, D.A.; Zou, J. Systematic analysis of 50 years of Stanford University technology transfer and commercialization. Patterns 2022, 3, 100584. [Google Scholar] [CrossRef]
- Fu, X.; Buckley, P.J.; Sanchez-Ancochea, D.; Hassan, I. The world has a unique opportunity: Accelerating technology transfer and vaccine production through partnerships. J. Int. Bus. Pol. 2022, 5, 406–415. [Google Scholar] [CrossRef]
- Vansovits, V.; Petlenkov, E.; Tepljakov, A.; Vassiljeva, K.; Belikov, J. Bridging the Gap in Technology Transfer for Advanced Process Control with Industrial Applications. Sensors 2022, 22, 4149. [Google Scholar] [CrossRef]
- Siegel, D.; Bogers, M.L.A.M.; Jennings, P.D.; Xue, L. Technology transfer from national/federal labs and public research institutes: Managerial and policy implications. Res. Pol. 2023, 52, 104646. [Google Scholar] [CrossRef]
- Garner, B.R.; Zehner, M.; Roosa, M.R.; Martino, S.; Gotham, H.J.; Ball, E.L.; Stilen, P.; Speck, K.; Vandersloot, D.; Rieckmann, T.R.; et al. 2nd Testing the implementation and sustainment facilitation (ISF) strategy as an effective adjunct to the Addiction Technology Transfer Center (ATTC) strategy: Study protocol for a cluster randomized trial. Addict. Sci. Clin. Pract. 2017, 12, 32. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sakolish, C.; Weber, E.J.; Kelly, E.J.; Himmelfarb, J.; Mouneimne, R.; Grimm, F.A.; House, J.S.; Wade, T.; Han, A.; Chiu, W.A.; et al. Technology Transfer of the Microphysiological Systems: A Case Study of the Human Proximal Tubule Tissue Chip. Sci. Rep. 2018, 8, 14882. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Weis, J.; Bashyam, A.; Ekchian, G.J.; Paisner, K.; Vanderford, N.L. Evaluating disparities in the U.S. technology transfer ecosystem to improve bench to business translation. F1000Research 2018, 7, 329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sun, Z.; Wang, M.; Zhang, W.; Li, Y.; Wang, D.; Dong, F. How Can We Improve the Transformation Success Rate of Research Results in the Pharmaceutical Industry? The Game Theoretic Model of Technology Transfer Subjects. Int. J. Environ. Res. Public Health 2019, 16, 1588. [Google Scholar] [CrossRef] [Green Version]
- Tsai, W. Knowledge transfer in intraorganizational networks: Effects of network position and absorptive capacity on business unit innovation and performance. Acad. Manag. Ann. 2001, 44, 996–1004. [Google Scholar] [CrossRef]
- Wahab, S.A.; Rose, R.C.; Osman, S.I.W. Defining the concepts of technology and technology transfer: A literature analysis. Int. Bus. Res. 2012, 5, 61–71. [Google Scholar] [CrossRef]
- Scandura, T.A.; Williams, E.A. Research methodology in management: Current practices, trends, and implications for future research. Acad. Manag. Ann. 2000, 43, 1248–1264. [Google Scholar] [CrossRef]
- Coviello, N.E.; Jones, M.V. Methodological issues in international entrepreneurship research. J. Bus. Ventur. 2004, 19, 485–508. [Google Scholar] [CrossRef]
- Salicrup, L.A.; Fedorková, L. Challenges and opportunities for enhancing biotechnology and technology transfer in developing countries. Biotechnol. Adv. 2006, 24, 69–79. [Google Scholar] [CrossRef]
- Hemmatian, I.; Ponzio, T.A.; Joshi, A.M. Exploring the role of R&D collaborations and non-patent IP policies in government technology transfer performance: Evidence from U.S. federal agencies (1999–2016). PLoS ONE 2022, 17, e0268828. [Google Scholar] [CrossRef]
- Śledzik, K.; Barembruch, A. Zastosowanie syntetycznych miar do konstrukcji Mapy Pozycji Konkurencyjnej przedsiębiorstw w aspekcie wydatków na B+R i wyniku finansowego. J. Manag. Fin. 2015, 13, 317–330. Available online: http://zif.wzr.pl/pim/2015_3_1_21.pdf (accessed on 19 October 2022).
- Śledzik, K. Multi-dimensional Competitive Position Analysis of Most Innovative Pharmaceutical & Biotechnology Companies—2012 Perspective. SSRN 2014. [Google Scholar] [CrossRef]
- Khalilia, M.; Chakraborty, S.; Popescu, M. Predicting disease risks from highly imbalanced data using random forest. BMC Med. Inform. Decis. Mak. 2011, 11, 51. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yifei, S.; Chengwei, H.; Weidong, Y.; Xin, L.; Li, M.; Zhenhuan, T. Diabetes Mellitus risk prediction using age adaptation models. Biomed. Signal Process. Control 2023, 80, 104381. [Google Scholar] [CrossRef]
- Kukuła, K. Metoda Unitaryzacji Zerowej; Wydawnictwo Naukowe PWN: Warsaw, Poland, 2000. [Google Scholar]
- Łuniewska, M.; Tarczyński, W. Metody Wielowymiarowej Analizy Porównawczej na Rynku Kapitałowym; Wydawnictwo Naukowe PWN: Warsaw, Poland, 2006. [Google Scholar]
- Balicki, A. Statystyczna Analiza Wielowymiarowa i Jej Zastosowania Społeczno-Ekonomiczne; Wydawnictwo Naukowe PWN: Warsaw, Poland, 2014. [Google Scholar]
Disease | Asia | Europe | Middle East | North America | South and Central America |
---|---|---|---|---|---|
Brest cancer | 6263 | 136,283 | 888 | 280,246 | 1552 |
Lung cancer | 7765 | 121,208 | 2503 | 281,072 | 2768 |
Cardiovascular | 17,720 | 185,175 | 5608 | 178,914 | 6081 |
Diabetes | 15,710 | 139,331 | 4511 | 157,097 | 10,991 |
Obesity | 5921 | 8186 | 4833 | 276,391 | 3872 |
Bladder cancer | 495 | 322 | 137 | 162,844 | 183 |
Neurodegenerative | 2438 | 5197 | n.a. | 122,260 | 27 |
Pancreatic cancer | 1540 | 4314 | 470 | 95,581 | 55 |
AIDS | 3674 | 50,472 | 1000 | 21,411 | 953 |
Prostate cancer | 1619 | 19,338 | 855 | 33,516 | 975 |
Allergies | 2823 | 9232 | 1363 | 36,538 | 1328 |
COVID-19 | 5690 | 12,044 | 666 | 17,250 | 1311 |
Depression | 3885 | 5179 | 3770 | 15,805 | 3765 |
Sum | 75,543 | 696,281 | 26,604 | 1,678,925 | 33,861 |
Phase | Step | Tool | Outcome | Part of the Paper |
---|---|---|---|---|
Defining and designing | 1. Identifying the problem | Literature review protocol | Research problem | Section 1, Section 2 and Section 2.1 |
2. Describing the method | Designing data collection and analysis | Literature review protocol | Section 3 | |
Preparing, collecting | 3. Conducting a data collection and preparation | Filled data protocol | Table A1, Table A2 and Table A3 | Appendix A |
4. Preparing results | Paper template | Results, Figure 1. | Section 3 and Section 4 | |
Analyzing and concluding | 5. Modifying or enhancing theory (if required) | Literature review protocol | Finished manuscript | Section 5 |
6. Concluding | Research report template, paper template | Finished manuscript | Section 6 |
Disease | SMTT | Position | SMTT_Value | Position | SMTT_Quantity | Position |
---|---|---|---|---|---|---|
Cardiovascular | 0.684 | 1 | 0.649 | 1 | 0.718 | 2 |
Diabetes | 0.633 | 2 | 0.523 | 2 | 0.765 | 1 |
COVID-19 | 0.347 | 3 | 0.274 | 5 | 0.416 | 3 |
Brest cancer | 0.306 | 4 | 0.316 | 4 | 0.298 | 5 |
Neurodegenerative | 0.285 | 5 | 0.262 | 6 | 0.305 | 4 |
Lung cancer | 0.274 | 6 | 0.325 | 3 | 0.233 | 9 |
Obesity | 0.238 | 7 | 0.211 | 7 | 0.263 | 6 |
Allergies | 0.234 | 8 | 0.209 | 8 | 0.257 | 7 |
AIDS | 0.209 | 9 | 0.174 | 9 | 0.241 | 8 |
Prostate cancer | 0.182 | 10 | 0.163 | 10 | 0.198 | 10 |
Depression | 0.132 | 11 | 0.124 | 11 | 0.140 | 11 |
Pancreatic cancer | 0.116 | 12 | 0.089 | 13 | 0.139 | 12 |
Bladder cancer | 0.067 | 13 | 0.117 | 12 | 0.025 | 14 |
Chronic obstructive pulmonary disease | 0.049 | 14 | 0.047 | 14 | 0.050 | 13 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Śledzik, K.; Płoska, R.; Chmielewski, M.; Barembruch, A.; Szmelter-Jarosz, A.; Kędzierska-Szczepaniak, A.; Antonowicz, P. Multivariate Pharma Technology Transfer Analysis: Civilization Diseases and COVID-19 Perspective. Int. J. Environ. Res. Public Health 2023, 20, 1954. https://doi.org/10.3390/ijerph20031954
Śledzik K, Płoska R, Chmielewski M, Barembruch A, Szmelter-Jarosz A, Kędzierska-Szczepaniak A, Antonowicz P. Multivariate Pharma Technology Transfer Analysis: Civilization Diseases and COVID-19 Perspective. International Journal of Environmental Research and Public Health. 2023; 20(3):1954. https://doi.org/10.3390/ijerph20031954
Chicago/Turabian StyleŚledzik, Karol, Renata Płoska, Mariusz Chmielewski, Adam Barembruch, Agnieszka Szmelter-Jarosz, Angelika Kędzierska-Szczepaniak, and Paweł Antonowicz. 2023. "Multivariate Pharma Technology Transfer Analysis: Civilization Diseases and COVID-19 Perspective" International Journal of Environmental Research and Public Health 20, no. 3: 1954. https://doi.org/10.3390/ijerph20031954
APA StyleŚledzik, K., Płoska, R., Chmielewski, M., Barembruch, A., Szmelter-Jarosz, A., Kędzierska-Szczepaniak, A., & Antonowicz, P. (2023). Multivariate Pharma Technology Transfer Analysis: Civilization Diseases and COVID-19 Perspective. International Journal of Environmental Research and Public Health, 20(3), 1954. https://doi.org/10.3390/ijerph20031954